LEXINGTON, Ky.--(BUSINESS WIRE)--Orthopeutics, LP, the parent company of Intralink Spine, Inc., Intrabrace, LLC, Tarexx, LLC, and Equinext, LLC, will soon be awarded its 7th US patent covering NEXTTM, a novel injectable treatment to repair degraded and painful spinal discs and other highly prevalent soft tissue disorders. The latest patent, US 8,283,322, addresses reagent formulations for their injectable tissue-repair products. Other US patents held by Orthopeutics cover treatments for spinal disc degradation, spinal deformity (scoliosis, kyphosis, and spondylolisthesis), tearing of the disc or knee meniscus, nutritional deficiencies that impede stem cell and cytokine therapies, and preventing expulsion of implanted devices or materials. Several international patents have also been issued and several more US and international patents are pending.
